论文部分内容阅读
目的 :研究卵巢癌组织中P170 g、GST π、Top Ⅱ表达及其与耐药的关系。 方法 :采用免疫组化的方法测定 31例初治、19例术后复发者卵巢癌组织中P170 g、GST π、Top Ⅱ的表达频率。 结果 :①卵巢癌组织中P170 g、GST π、Top Ⅱ表达频率分别为 4 4 % ( 2 /50 )、60 % ( 30 /50 )、4 2 % ( 2 1/50 )。② 31例初治患者卵巢癌组织中三者阳性表达率分别为 35 5% ( 11/31)、4 8 4 % ( 15/31)、54 84 % ( 17/31)。 19例复发患者三者阳性表达率分别为 57 9% ( 11/19)、78 9% ( 15/19)、2 1 1% ( 4 /19)。初治与复发者中GST π、Top Ⅱ表达差异有显著性 (P <0 0 5)。③GST π阳性者化疗有效率 ( 36 67% )明显低于GST π阴性者 ( 70 % ) ,GST π阳性者预后较差。结论 :卵巢癌组织中GST π和Top Ⅱ表达与其化疗耐药有关 ,GST π可作为判断化疗敏感性及预后的因素之一。
Objective: To study the expression of P170 g, GST π, Top Ⅱ in ovarian cancer and its relationship with drug resistance. Methods: Immunohistochemical method was used to determine the expression frequency of P170 g, GST π, Top Ⅱ in 31 cases of newly diagnosed and 19 cases of postoperative recurrence of ovarian cancer. Results ① The frequencies of P170 g, GST π and Top Ⅱ in ovarian cancer tissues were 44% (2/50), 60% (30/50) and 42% (2 1/50) respectively. ② The positive expression rates of three of the 31 untreated patients with ovarian cancer were 35 5% (11/31), 444% (15/31) and 54 84% (17/31), respectively. The positive rates of the three of the 19 relapsed patients were 57 9% (11/19), 78 9% (15/19) and 21 1% (4/19), respectively. There was a significant difference in GST π and Top Ⅱ between newly diagnosed and relapsed patients (P <0.05). ③GST π-positive chemotherapy (36 67%) was significantly lower than GST π negative (70%), GST π positive prognosis is poor. Conclusion: The expression of GST π and Top Ⅱ in ovarian cancer is related to chemoresistance. GST π can be used as one of the factors to judge the sensitivity and prognosis of chemotherapy.